Salud financiera de hoja de balance de Core One Labs

Salud financiera controles de criterios 0/6

Datos insuficientes para determinar la salud financiera de Core One Labs

Información clave

n/a

Ratio deuda-patrimonio

n/a

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	n/a
Patrimonio	n/a
Total pasivo	n/a
Activos totales	n/a

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Datos insuficientes para determinar si los activos a corto plazo de CLAB.F cubren sus pasivos a corto plazo.

Pasivo a largo plazo: Datos insuficientes para determinar si los activos a corto plazo de CLAB.F cubren sus pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: Datos insuficientes para calcular el ratio deuda neta-patrimonio de CLAB.F para determinar si es satisfactorio.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de CLAB.F se ha reducido en los últimos 5 años.

Cobertura de la deuda: Datos insuficientes para determinar si la deuda de CLAB.F está bien cubierta por el flujo de caja operativo.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de CLAB.F sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Core One Labs

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera